CBS News Staffers on the Verge of Revolt If This Person Is Hired
As Puerto Ricans Call for Independence Their Dreams Are Blocked By Their Chief...
President Trump Closes the Overton Window
The Fake Stream Media’s Pervasive Assault on Black America
Mamdani: More Continuation Than Aberration for New York
President Trump Is Bringing the Spirit of Sports Back to America
Money, Power and Transgender Ideology
Cleaning Up the Swamp Is a Full-Time Job for Trump
Iran's Mullahs Staring Into the Abyss
The Party of Losers Is Not Funny
The Enduring Lie of Socialism
DOJ: Minnesota Duo Orchestrated Kidnappings, Bombings in Africa
Michigan Woman Indicted for Smuggling Illegal Aliens, Children, Across the Northern Border
Tennessee Joins 25-State Coalition Defending Second Amendment Rights for Travelers
DOD Calls Out 'Highly Provocative' Move by Venezuela
Tipsheet

FDA Delays Review of COVID-19 Vaccine for Children Under 5 Years Old

AP Photo/Ted Jackson

The U.S. Food and Drug Administration (FDA) delayed its review of Pfizer’s COVID-19 vaccine for children under 5 years old because the initial two-dose vaccine regimen was not working well to protect against the Omicron variant during tests, the Wall Street Journal reported Friday. 

Advertisement

Sources who are familiar with the decision told WSJ that earlier data showed the vaccine to be effective against the Delta variant during testing. At the time, Delta was the dominant strain of COVID-19. Since then, some vaccinated children have developed COVID-19 after the onset of the Omicron variant.

“So few study subjects, whether vaccinated or unvaccinated, developed Covid-19 during testing thus far that the small number of Omicron cases made the vaccine appear less effective in an early statistical analysis, the people said.

As more cases emerge, Pfizer’s shot might wind up providing stronger protection against Omicron, the people said, if the bulk of infections are in unvaccinated subjects.

Officials from the Food and Drug Administration and Pfizer agreed it would be better to wait for the additional cases, the people said. The extra time would let the agency assess the vaccine’s effectiveness as either two doses or three, they said. The FDA was going to make its decision by looking at whether the shot generated immune responses comparable with those seen in older people.

The delay will also allow regulators to see how a third dose performs, the people said. That additional dose is given at least two months after the second shot. The FDA hopes to have a decision on the vaccine this spring, the people said; Pfizer has said it expects study results in early April.”

Advertisement

This month, I covered how Pfizer and its partner BioNTech planned to submit a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for their coronavirus vaccine for children 6 months to 5 years old. Sources briefed on the matter told The Washington Post that the FDA urged the companies to submit the application so that vaccine regulators could review the data. However, the data showed “disappointing” vaccine protection results for certain age groups.

In December, an announcement published from Pfizer indicated that trials of its vaccine in children 2 to 5 years old did not produce the level of protection that was expected. The announcement stated that the trials would be “amended” to include evaluating a third vaccine dose at least two months after the second dose of the initial two-dose series to provide “high levels of protection” for this age demographic.

The WSJ’s Friday report noted that “the decision to wait, which came days before the FDA was expected to make its determination [on vaccinating children 5 and under] angered some parents who were eager to vaccinate their young children and confused others unsure of what to do.”

Advertisement

Late last year, the FDA approved Emergency Use Authorization for Pfizer’s vaccine for children ages 5 to 11. A survey conducted by the Kaiser Family Foundation found that only 27 percent of parents were “eager” to vaccinate their 5 to 11 year old children, while 30 percent said that they will “definitely” not vaccinate their 5 to 11 year old children. Thirty-three percent said they would wait and see how the vaccine is working before getting their children vaccinated.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement